Tag: Trifluoroacetyl hydrazone geroneuroprotector with AMPK-mediated neuroprotective and neurogenic activity

  • CAD-31

    Trifluoroacetyl hydrazone geroneuroprotector with AMPK-mediated neuroprotective and neurogenic activity

    A synthetic trifluoroacetyl hydrazone derived from the curcumin scaffold via four generations of phenotypic optimization at the Salk Institute, selected for combined neuroprotective and neurogenic activity in human neural precursor cells, with preclinical efficacy in transgenic Alzheimer’s disease and accelerated-aging mouse models through AMPK-dependent modulation of fatty acid metabolism, inflammation, and acetyl-CoA homeostasis.

    Abstract

    CAD-31 (CAD-031; CAS 2071209-49-7) is a synthetic trifluoroacetyl hydrazone (molecular weight 404.31, C18H14F6N2O2) derived from the curcumin scaffold through four generations of phenotypic optimization at the Cellular Neurobiology Laboratory of the Salk Institute for Biological Studies. The compound was selected from a library of more than 200 derivatives of the parent compound J147 on the basis of superior potency in a human embryonic stem cell-derived neural precursor cell (hNPC) neurogenesis assay and retention of broad neuroprotective activity across six cell culture models of age-associated brain toxicity [1, 2]. In assays for trophic factor withdrawal, oxidative stress (oxytosis), in vitro ischemia, extracellular and intracellular amyloid-beta toxicity, and BDNF-like neurotrophic activity, CAD-31 demonstrates EC50 values in the range of 12 to 95 nanomolar, comparable to J147 in most assays and superior in the trophic factor withdrawal model [1]. Neurogenesis markers in human neural precursor cells (nestin, Pax6, doublecortin, Ki67) are elevated 2.6- to 5.2-fold relative to J147 at matched concentrations, representing the distinctive pharmacological advance of CAD-31 within the compound series [2]. The molecular mechanism of CAD-31 converges on the AMP-activated protein kinase (AMPK) signaling cascade. CAD-31 activates AMPK by phosphorylation at threonine 172 and inhibits the downstream target acetyl-CoA carboxylase 1 (ACC1) by phosphorylation at serine 79, resulting in elevated acetyl-CoA levels, reduced free fatty acid synthesis, and increased ketone body availability in the brain [1, 6]. This metabolic reprogramming is accompanied by reductions in inflammatory markers (vascular cell adhesion molecule, receptor for advanced glycation endproducts, clusterin) and increases in synaptic proteins (drebrin, activity-regulated cytoskeleton-associated protein) in hippocampal tissue of transgenic Alzheimer’s disease mice [1]. In rapidly aging SAMP8 mice, CAD-31 extended median lifespan by approximately 30 percent when administered in the final quarter of life, with corresponding preservation of youthful gene, protein, and metabolite expression profiles in the brain [6]. Preclinical safety screening shows no acute toxicity at 2 g/kg, no activity in hERG, Ames, or micronucleus assays, and no inhibition of five major cytochrome P450 enzymes at concentrations more than tenfold above the effective range [1]. No formal molecular target has been identified for CAD-31; the parent compound J147 binds the alpha-F1 subunit of mitochondrial ATP synthase (ATP5A), and CAD-31 likely engages the same or a closely related target given the shared downstream AMPK activation and neuroprotective phenotype [7, 8]. CAD-31 has not entered human clinical trials. The parent compound J147 completed a Phase 1 safety study (NCT03838185), and the related compound CMS121 has received National Institutes of Health funding for Investigational New Drug studies [5]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.